Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

universities

Roche - Basel

Roche’s MEK inhibitor boosts Zelboraf efficacy in melanoma

Could give edge to Swiss company as new skin cancer treatments see growth

- PMLiVE

Eisai’s Bose to join Boehringer

He becomes head of global marketing for oncology

Excellence in oncology: Developing an effective biomarker strategy

Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...

Research Partnership

- PMLiVE

Cancer drug nivolumab wins PD1 inhibitor race to market

BMS and Ono’s skin cancer treatment approved in Japan under trade name Opdivo

Roche - Basel

Roche makes $1.7bn oncology acquisition

Takes over Seragon and its pipeline of investigational breast cancer treatments

- PMLiVE

Merck could win anti-PD1 therapy race in Europe

EMA accepts filing for promising pembrolizumab in melanoma

- PMLiVE

Erbitux betters Avastin in bowel cancer subgroup

Data backs Merck KGaA drug over Roche’s rival in RAS wild-type metastatic colorectal cancer

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

- PMLiVE

Niche-busting cancer immunotherapies

Targeted oncology treatments are a reason for hope

- PMLiVE

Merck KGaA furthers antibody ambitions in cancer

Signs deal with Mersana to develop antibody-drug conjugates

- PMLiVE

Pfizer turns to cancer immunotherapies

Signs deal with French company Cellectis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links